Navigating the regulatory landscape of the Bacterial Endotoxin Test (BET) involves a thorough review of guidelines from regulatory agencies such as the FDA, USP, and...

Key Findings• Every month a programme can accelerate to market adds an estimated $5–6M of net present value per billion dollars of peak year sales• We have identifie...

The bone marrow niche provides a tightly controlled setting where cellular interactions, biochemical signalling, and mechanical stimuli collectively shape the fate o...

Antibodies represent a rapidly growing therapeutic modality, demonstrating clinical success over a wide variety of diseases, including cancer, autoimmune disorders, ...

What is Biopharma 4.0? Biopharma 4.0 refers to the next-generation modernisation approach to biopharmaceutical development, manufacturing, and quality. It integrates...

Targeted Protein Degraders (TPDs) are transforming the landscape of modern drug discovery and development, introducing a ground-breaking method for tackling diseases...

The life science industry faces the challenges of developing and delivering life-changing medicines at an accelerated pace, all while maintaining quality and safety ...

AI use cases are rippling across commercial biopharma, helping companies make faster, more informed decisions. Yet almost 70% of top generative AI (GenAI) users cite...

When anything changes to a product’s make-up or manufacture, a whole chain of events is triggered, starting with an assessment of the regulatory impact in each regul...

When investigational medicinal products (IMPs) are exposed to conditions outside of their approved storage range, sponsors need to be ready to act or risk the integr...